CytomX Therapeutics, Inc.CTMXNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank8
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Latest
-21.09%
↓ 249% vs avg
Percentile
P8
Near historical low
Streak
1 yr
Consecutive declineDecelerating
Average
14.14%
Historical baseline
PeriodValue
2025-21.09%
20247.34%
2023-30.42%
2022-2.23%
20211.11%
2020-14.19%
201926.72%
201812.56%
201768.53%
201693.09%